Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Thermocrinis

ABSTRACT: Thermocrinis sp. overview

PROVIDER: PRJNA196191 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	JNIE01.dat.gz	Other
	JNIE01.fasta.gz	Fasta.gz
	JNIE01.master.dat	Other
	SRR3500579.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 5

Similar Datasets

Thermocrinis ruber

Project description:Thermocrinis ruber overview

| PRJNA75257 | ENA

Thermocrinis albus DSM 14484

Project description:Thermocrinis albus DSM 14484 Genome Sequencing

| PRJNA37275 | ENA

Thermocrinis jamiesonii strain:GBS

Project description:Thermocrinis jamiesonii strain:GBS Genome sequencing and assembly

| PRJNA195645 | ENA

Thermocrinis ruber strain:DSM 23557

Project description:Thermocrinis ruber strain:DSM 23557 Genome sequencing

| PRJNA75073 | ENA

Thermocrinis minervae strain:DSM 19557 | isolate:DSM 19557

Project description:Thermocrinis minervae DSM 19557 genome sequencing

| PRJNA331528 | ENA

Thermocrinis albus

Project description:Filament-forming thermophile

| PRJNA37287 | ENA

Project description:Thermocrinis minervae DSM 19557

| PRJEB18353 | ENA

Complete genome sequence of Thermocrinis albus type strain (HI 11/12).

Project description:Thermocrinis albus Eder and Huber 2002 is one of three species in the genus Thermocrinis in the family Aquificaceae. Members of this family have become of significant interest because of their involvement in global biogeochemical cycles in high-temperature ecosystems. This interest had already spurred several genome sequencing projects for members of the family. We here report the first completed genome sequence a member of the genus Thermocrinis and the first type strain genome from a member of the family Aquificaceae. The 1,500,577 bp long genome with its 1,603 protein-coding and 47 RNA genes is part of the Genomic Encyclopedia of Bacteria and Archaea project.

| S-EPMC3035279 | biostudies-literature

Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutations [Methylation]

Project description:Background: Ependymomas encompass multiple, clinically relevant tumor types based on localization and molecular profiles. Although tumors of the methylation class “spinal ependymoma” (SP-EPN) represent the most common intramedullary neoplasms in children and adults, their developmental origin is ill-defined, molecular data are scarce, and the potential heterogeneity within SP-EPN remains unexplored. The only known recurrent genetic events in SP-EPN are loss of chromosome 22q and NF2 mutations, but neither types and frequency of these alterations nor their clinical meaning have been described in a large, epigenetically defined series. Methods: We mapped SP-EPN transcriptomes (n=76) to developmental atlases of the developing and adult spinal cord to uncover potential developmental origins of these tumors. In addition, transcriptomic, epigenetic (n=234), genetic (n=140), and clinical analyses (n=115) were integrated for a detailed overview on this entity. Results: Integration of transcriptomic ependymoma data with single-cell atlases of the spinal cord identified mature adult ependymal cells to display highest similarities to SP-EPN. Unsupervised hierarchical clustering of tumor data together with integrated analysis of methylation profiles identified two molecular SP-EPN subtypes. Subtype 1 predominantly contained NF2 wild type sequences with regular NF2 expression but revealed more extensive copy number alterations. Subtype 2 harbored previously known germline or sporadic NF2 mutations and was NF2-deficient in most cases, more often showed multilocular disease, and demonstrated a significantly reduced progression-free survival. Conclusion: Based on integrated molecular profiling of a large tumor series we identify two distinct SP-EPN subtypes with important implications for genetic counseling, patient surveillance, and drug development priorities.

2024-01-26 | GSE242991 | GEO